Effects of Silodosin on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia: Evaluation by Frequency/Volume Chart

• Published in: Lower urinary tract symptoms Vol. 2; no. 1; p. 31
• Main Authors: Watanabe, Miho, Yamanishi, Tomonori, Mizuno, Tomoya, Tatsumiya, Katsuhisa, Masuda, Akinori, Honda, Mikihiko, Uchiyama, Tomoyuuki, Sakakibara, Ryuji, Yoshida, Ken-Ichiro
• Format: Journal Article
• Language: English
• Published: Australia 01.04.2010
• Subjects: frequency/volume chart; lower urinary tract symptoms; silodosin; alpha blocker; benign prostate hyperplasia
• ISSN: 1757-5664
• DOI: 10.1111/j.1757-5672.2010.00059.x

To prospectively evaluate the efficacy of silodosin, a new α1A -adrenoceptor selective antagonist, for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) on the basis of a frequency/volume chart. Forty male patients (71.1 ± 6.6 years old) with LUTS/BPH were treated with silodosin (4 mg twice daily). The effects of the drug were assessed by changes in International Prostate Symptom Score, uroflowmetry, and frequency/volume chart at 1 and 3 months after therapy. The mean total International Prostate Symptom Score, the mean total storage and voiding scores and the mean quality of life score decreased significantly at 1 and 3 months after therapy (all P < 0.01). Average and maximum flow rates increased significantly, and postvoid residual volume decreased significantly after 1 and 3 months (all P < 0.05). The frequency/volume chart showed that daytime frequency in those who initially voided over eight times/day (n = 12) decreased significantly (P = 0.0391) after 1 month, and nighttime frequency in those who initially voided over two times (n = 16) tended to decrease (P = 0.0833) after 3 months. Mean voided volume in those who initially voided less than 250 mL (n = 31) increased significantly after 1 and 3 months (P = 0.0446 and P = 0.0138, respectively), and maximum voided volume in those who initially voided less than 300 mL (n = 18) tended to increase (P = 0.0833) after 1 month. Silodosin appears to be effective for both storage and voiding symptoms by increasing bladder capacity in patients with LUTS/BPH.